Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 69 articles: HTML format Text format

Single Articles

May 2019
1. DE FIGUEIREDO A, Were F
   Local trends in immunisation coverage across Africa.
   Lancet. 2019;393:1779-1781.
   PubMed     Text format    
   
   
   April 2019
2. ADEPOJU P
   RTS,S malaria vaccine pilots in three African countries.
   Lancet. 2019;393:1685.
   PubMed     Text format    
   
   
   
3. HAMMITT LL, Etyang AO, Morpeth SC, Ojal J, et al
   Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
   Lancet. 2019 Apr 15. pii: S0140-6736(18)33005.
   PubMed     Text format     Abstract available
   
   
   
4. KLUGMAN KP, Rodgers GL
   Population versus individual protection by pneumococcal conjugate vaccination.
   Lancet. 2019 Apr 15. pii: S0140-6736(19)30039.
   PubMed     Text format    
   
   
   
5. MOSSER JF, Gagne-Maynard W, Rao PC, Osgood-Zimmerman A, et al
   Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study.
   Lancet. 2019 Apr 5. pii: S0140-6736(19)30226.
   PubMed     Text format     Abstract available
   
   
   March 2019
6. NAYAR RK, Nair AT, Shaffi M, Swarnam K, et al
   Methods to overcome vaccine hesitancy.
   Lancet. 2019;393:1203-1204.
   PubMed     Text format    
   
   
   
7. THE LANCET
   Canada's mandatory vaccination reporting plans.
   Lancet. 2019;393:960.
   PubMed     Text format    
   
   
   
8. ZHAO F, Qiao Y
   Cervical cancer prevention in China: a key to cancer control.
   Lancet. 2019;393:969-970.
   PubMed     Text format    
   
   
   
9. MALVY D, McElroy AK, de Clerck H, Gunther S, et al
   Ebola virus disease.
   Lancet. 2019;393:936-948.
   PubMed     Text format     Abstract available
   
   
   
10. GAUDINSKI MR, Coates EE, Novik L, Widge A, et al
    Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
    Lancet. 2019;393:889-898.
    PubMed     Text format     Abstract available
    
    
    February 2019
11. GOSTIN L, Phelan A, Coutinho AG, Eccleston-Turner M, et al
    Ebola in the Democratic Republic of the Congo: time to sound a global alert?
    Lancet. 2019 Feb 1. pii: S0140-6736(19)30243.
    PubMed     Text format    
    
    
    January 2019
12. WILDER-SMITH A, Ooi EE, Horstick O, Wills B, et al
    Dengue.
    Lancet. 2019;393:350-363.
    PubMed     Text format     Abstract available
    
    
    
13. COHEN PA, Jhingran A, Oaknin A, Denny L, et al
    Cervical cancer.
    Lancet. 2019;393:169-182.
    PubMed     Text format     Abstract available
    
    
    
14. THE LANCET
    Cervical cancer: unequal progress.
    Lancet. 2019;393:104.
    PubMed     Text format    
    
    
    November 2018
15. LARSON HJ
    The state of vaccine confidence.
    Lancet. 2018;392:2244-2246.
    PubMed     Text format    
    
    
    
16. THE LANCET
    Looking beyond the Decade of Vaccines.
    Lancet. 2018;392:2139.
    PubMed     Text format    
    
    
    
17. CHANDLER J
    Fighting a polio outbreak in Papua New Guinea.
    Lancet. 2018;392:2155-2156.
    PubMed     Text format    
    
    
    
18. POWERS AM
    Licensed chikungunya virus vaccine: a possibility?
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32809.
    PubMed     Text format    
    
    
    
19. REISINGER EC, Tschismarov R, Beubler E, Wiedermann U, et al
    Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Lancet. 2018 Nov 5. pii: S0140-6736(18)32488.
    PubMed     Text format     Abstract available
    
    
    October 2018
20. CLAUDE KM, Underschultz J, Hawkes MT
    Ebola virus epidemic in war-torn eastern DR Congo.
    Lancet. 2018;392:1399-1401.
    PubMed     Text format    
    
    
    
21. MARKS F, Kim JH, Rakotozandrindrainy R
    Madagascar should introduce typhoid conjugate vaccines now.
    Lancet. 2018;392:1309-1310.
    PubMed     Text format    
    
    
    September 2018
22. ZIMMER BL, Gamble L, Mayer D, Foster R, et al
    Canine rabies vaccination reduces child rabies cases in Malawi.
    Lancet. 2018;392:1115-1116.
    PubMed     Text format    
    
    
    
23. PRUE G, Baker P, Graham D, Nutting C, et al
    It is time for universal HPV vaccination.
    Lancet. 2018;392:913-914.
    PubMed     Text format    
    
    
    
24. BURKI T
    Cochrane review methods called into question.
    Lancet. 2018;392:906.
    PubMed     Text format    
    
    
    
25. HOLT E
    41 000 measles cases in Europe since the beginning of 2018.
    Lancet. 2018;392:724.
    PubMed     Text format    
    
    
    August 2018
26. HAYFLICK L
    Subject of The Vaccine Race offers perspective on errors.
    Lancet. 2018;392:633-634.
    PubMed     Text format    
    
    
    
27. LEVY Y, Lane C, Piot P, Beavogui AH, et al
    Prevention of Ebola virus disease through vaccination: where we are in 2018.
    Lancet. 2018 Aug 10. pii: S0140-6736(18)31710.
    PubMed     Text format    
    
    
    
28. THE LANCET
    Vaccine scandal and confidence crisis in China.
    Lancet. 2018;392:360.
    PubMed     Text format    
    
    
    
29. GREEN A
    HPV vaccine to be offered to boys in England.
    Lancet. 2018;392:374.
    PubMed     Text format    
    
    
    
30. YUAN X
    China's vaccine production scare.
    Lancet. 2018;392:371.
    PubMed     Text format    
    
    
    
31. FRASER B
    Measles outbreak in the Americas.
    Lancet. 2018;392:373.
    PubMed     Text format    
    
    
    July 2018
32. BAROUCH DH, Tomaka FL, Wegmann F, Stieh DJ, et al
    Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
    Lancet. 2018;392:232-243.
    PubMed     Text format     Abstract available
    
    
    
33. PAVLAKIS GN, Felber BK
    A new step towards an HIV/AIDS vaccine.
    Lancet. 2018;392:192-194.
    PubMed     Text format    
    
    
    
34. LEWNARD JA
    Ebola virus disease: 11 323 deaths later, how far have we come?
    Lancet. 2018;392:189-190.
    PubMed     Text format    
    
    
    
35. DEVI S
    Setbacks in the fight to eradicate polio.
    Lancet. 2018;392:201-202.
    PubMed     Text format    
    
    
    
36. BANYAI K, Estes MK, Martella V, Parashar UD, et al
    Viral gastroenteritis.
    Lancet. 2018;392:175-186.
    PubMed     Text format     Abstract available
    
    
    June 2018
37. GREEN A
    DR Congo: investigational research against Ebola virus.
    Lancet. 2018;391:2308-2309.
    PubMed     Text format    
    
    
    May 2018
38. WINSTON DJ, Mullane KM, Cornely OA, Boeckh MJ, et al
    Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2018;391:2116-2127.
    PubMed     Text format     Abstract available
    
    
    
39. CORCORAN B, Clarke A, Barrett T
    Rapid response to HPV vaccination crisis in Ireland.
    Lancet. 2018;391:2103.
    PubMed     Text format    
    
    
    
40. MACARTNEY K, Gershon AA
    Shingles vaccine after auto-HSCT decreases risk.
    Lancet. 2018;391:2082-2084.
    PubMed     Text format    
    
    
    
41. KELLY JD, Mukadi P, Dhillon RS
    Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
    Lancet. 2018 May 25. pii: S0140-6736(18)31212.
    PubMed     Text format    
    
    
    
42. QADRI F, Azad AK, Flora MS, Khan AI, et al
    Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.
    Lancet. 2018;391:1877-1879.
    PubMed     Text format    
    
    
    
43. AGUIAR M
    Dengue vaccination: a more ethical approach is needed.
    Lancet. 2018;391:1769-1770.
    PubMed     Text format    
    
    
    
44. HARGREAVES S, Nellums LB, Ramsay M, Saliba V, et al
    Who is responsible for the vaccination of migrants in Europe?
    Lancet. 2018;391:1752-1754.
    PubMed     Text format    
    
    
    April 2018
45. THE LANCET
    Addressing decreasing vaccine coverage in the EU.
    Lancet. 2018;391:1638.
    PubMed     Text format    
    
    
    
46. CHEN S, Li J, Wang D, Fung H, et al
    The hepatitis B epidemic in China should receive more attention.
    Lancet. 2018;391:1572.
    PubMed     Text format    
    
    
    March 2018
47. PENG X, Hu X, Salazar MA
    On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine.
    Lancet. 2018 Mar 28. pii: S0140-6736(18)30483.
    PubMed     Text format    
    
    
    
48. WATTS G
    New York Challenge sets high bar for HPV vaccination.
    Lancet. 2018;391:1137.
    PubMed     Text format    
    
    
    
49. METZGER WG, Vivas-Martinez S
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
    Lancet. 2018;391:1021.
    PubMed     Text format    
    
    
    
50. LONGINI IM, Rottingen JA, Kieny MP, Edmunds WJ, et al
    Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
    Lancet. 2018;391:1021-1022.
    PubMed     Text format    
    
    
    February 2018
51. PANG T, Gubler D, Goh DYT, Ismail Z, et al
    Dengue vaccination: a more balanced approach is needed.
    Lancet. 2018;391:654.
    PubMed     Text format    
    
    
    
52. LARSON HJ
    A global girl gang.
    Lancet. 2018;391:527-528.
    PubMed     Text format    
    
    
    
53. PAULES CI, Subbarao K
    Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
    Lancet. 2018;391:427-428.
    PubMed     Text format    
    
    
    
54. CALDEIRA D, Ferreira JJ, Costa J
    Influenza vaccination and prevention of cardiovascular disease mortality.
    Lancet. 2018;391:426-427.
    PubMed     Text format    
    
    
    
55. THE LANCET
    Yellow fever: a major threat to public health.
    Lancet. 2018;391:402.
    PubMed     Text format    
    
    
    January 2018
56. THE LANCET
    Preparing for seasonal influenza.
    Lancet. 2018;391:180.
    PubMed     Text format    
    
    
    
57. THE LANCET
    A new vaccine for typhoid control.
    Lancet. 2018;391:96.
    PubMed     Text format    
    
    
    
58. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
    Pitfalls of the healthy vaccinee effect - Authors' reply.
    Lancet. 2018;391:123-124.
    PubMed     Text format    
    
    
    
59. MAHMUD SM, Righolt CH
    Pitfalls of the healthy vaccinee effect.
    Lancet. 2018;391:123.
    PubMed     Text format    
    
    
    
60. ZAFFRAN M, McGovern M, Hossaini R, Martin R, et al
    The polio endgame: securing a world free of all polioviruses.
    Lancet. 2018;391:11-13.
    PubMed     Text format    
    
    
    December 2017
61. MARQUES ETA, Burke DS
    Tradition and innovation in development of a Zika vaccine.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33107.
    PubMed     Text format    
    
    
    
62. GAUDINSKI MR, Houser KV, Morabito KM, Hu Z, et al
    Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33105.
    PubMed     Text format     Abstract available
    
    
    
63. MODJARRAD K, Lin L, George SL, Stephenson KE, et al
    Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
    Lancet. 2017 Dec 4. pii: S0140-6736(17)33106.
    PubMed     Text format     Abstract available
    
    
    October 2017
64. YIN Y
    HPV vaccination in China needs to be more cost-effective.
    Lancet. 2017;390:1735-1736.
    PubMed     Text format    
    
    
    September 2017
65. JIN C, Gibani MM, Moore M, Juel HB, et al
    Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32149.
    PubMed     Text format     Abstract available
    
    
    
66. FEASEY NA, Levine MM
    Typhoid vaccine development with a human challenge model.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32407.
    PubMed     Text format    
    
    
    
67. HUH WK, Joura EA, Giuliano AR, Iversen OE, et al
    Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Lancet. 2017 Sep 5. pii: S0140-6736(17)31821.
    PubMed     Text format     Abstract available
    
    
    
68. DENNY L
    Nine-valent human papillomavirus vaccine: great science, but will it save lives?
    Lancet. 2017 Sep 5. pii: S0140-6736(17)32144.
    PubMed     Text format    
    
    
    November 2016
69. DENNY L, de Sanjose S, Mutebi M, Anderson BO, et al
    Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
    Lancet. 2016 Nov 1. pii: S0140-6736(16)31795.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: